Ascendis Pharma A/S

NASDAQ:ASND

Biotechnology

Healthcare
$270.33 -0.02%

-$0.05 today

Market cap
$17.73B
Beta
0.39
P/E (TTM)
24.5
EPS (TTM)
$8.21
52W Low $160.86High $250.74

Volume 0.57M

Average 0.64M

ASND Interest Income

Income earned on cash, deposits, and investments held by the company.

Ascendis Pharma A/SNASDAQ: ASND

Interest Income · Q3 FY2026 · quarter ended Sep 2026

Interest income grows, but more slowly than its trailing trend

Q3 FY2026 interest income of €7.66M rose 130.3% year over year, behind the +172.4% change in trailing-twelve-month interest income. Sequentially, it fell 62.3% from the prior quarter. Over 3 fiscal years it compounded at +25.6% a year.

Context

  • Interest income amounted to 2.1% of revenue in FY2025, down 1.8 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +130.3% toward the trailing-twelve-month pace of +172.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
€7.66M-62.3% QoQ
Last fiscal yearDec 2025
€14.7M+2.3% YoY
LTMSep 2026
€56.37M+172.4% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+130.3%——
1 year+2.3%——
3-year CAGR+25.6%——
5-year CAGR——
10-year CAGR——

Interest Income history

EUR · from the income statement

Latest · FY2025
14.7M EUR
Year-over-year change
+2.3%
4-year CAGR
+114.7%

Interest Income vs competitors

How ASND compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +172.4% is the 2nd highest of 11, against a peer median of -22.5%.
  • Interest income amounts to 4.7% of revenue for ASND, versus a peer median of 3.6%.
ASND Competitors
Interest Income for ASND and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$4.68B USD+6281.3%+60.7%0.5%
UTHRUnited Therapeutics CorporationLTM Jun 2026$162.9M USD-19.2%+62.0%5.2%
ASNDAscendis Pharma A/SLTM Sep 2026€56.37M EUR+172.4%+25.6%4.7%
INSMInsmed IncorporatedLTM Jun 2026$45.57M USD-25.8%+76.2%4.0%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$24.17M USD-30.0%+31.2%3.6%
SEPNSepterna, Inc.LTM Sep 2026$20.44M USD+12.9%—21.2%
CORTCorcept Therapeutics IncorporatedLTM Jun 2026$15.33M USD-36.8%+82.6%1.8%
STOKStoke Therapeutics, Inc.LTM Mar 2026$10.88M USD-17.0%+64.0%33.9%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$4.77M USD+4.3%+22.5%1.5%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$4.16M USD-60.0%+210.0%—
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026-$14.7M USD-122.8%+100.5%0.4%
Peer median (excluding ASND) —-22.5%+64.0%3.6%

Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.78M51.17M266.72M363.64M691.71M
Cost of Revenue3.52M12.14M44.4M44.26M103.18M
Gross Profit4.26M39.04M222.32M319.38M588.53M
Gross Margin54.7%76.3%83.4%87.8%85.1%
Research & Development295.87M379.62M413.45M307M283.5M
Selling, General & Admin160.18M215.85M258.79M284.55M435.92M
Operating Expenses456.05M600.85M677.86M598.15M719.42M
Depreciation & Amortization15.39M17.96M18.91M17.71M17M
EBITDA(364.64M)(529.18M)(411.17M)(290.02M)(109.8M)
EBITDA Margin-4688.1%-1034.1%-154.2%-79.8%-15.9%
Operating Income(451.79M)(561.81M)(455.54M)(278.76M)(130.89M)
Operating Margin-5808.6%-1097.9%-170.8%-76.7%-18.9%
Interest Income692K7.43M16.86M14.36M14.7M
Interest Expense3.91M30.68M44.07M65.5M77.46M
Other Income / Expenses67.85M(16M)(18.6M)(94.48M)(73.37M)
Income Before Tax(383.94M)(577.82M)(474.14M)(373.24M)(204.26M)
Pre-Tax Margin-4936.3%-1129.1%-177.8%-102.6%-29.5%
Income Tax Expense(367K)5.38M7.3M4.84M14.78M
Net Income(383.58M)(583.19M)(481.45M)(378.08M)(219.03M)
Net Margin-4931.6%-1139.6%-180.5%-104.0%-31.7%
EPS (Basic)(7.00)(10.40)(8.55)(6.53)(3.62)
EPS (Diluted)(7.00)(10.40)(8.55)(6.53)(3.62)
Weighted Avg Shares54.77M56.07M56.29M57.89M60.61M
Weighted Avg Shares (Diluted)54.77M56.07M56.29M57.89M60.61M

Ascendis Pharma A/S

NASDAQ:ASND

Intrinsic Alpha fair value

Locked

Current Price

$270.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.